Evidence map›Paper›PMID 38814864›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution.

Bingqian Qu, Csaba Miskey, André Gömer, Robin D V Kleinert, Sara Calvo Ibanez, Regina Eberle, Aileen Ebenig, Dylan Postmus, Maximilian K Nocke, Maike Herrmann and 20 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Bingqian QuDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0002-7330-2929
Csaba MiskeyDivision of Medical Biotechnology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
André GömerDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.
Robin D V KleinertDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Sara Calvo IbanezElectron Microscopy of Pathogens, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID <0009-0004-3145-6112
Regina EberleElectron Microscopy of Pathogens, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Aileen EbenigDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0001-7066-0184
Dylan PostmusDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
Maximilian K NockeDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.ORCID 0000-0003-4632-525X
Maike HerrmannDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0002-0832-3539
Tabitha K ItotiaDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0002-7521-0155
Simon T HerrmannDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.
Natalie HeinenDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.ORCID 0000-0003-0906-5073
Sebastian HöckDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Florian D HastertDivision of Virology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Christine von RheinDivision of Virology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Christoph SchürmannDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0003-1530-1378
Xue LiDepartment of Cardiology, Medical University Hospital, 69120 Heidelberg, Germany.
Ger van ZandbergenDivision of Immunology, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Marek WideraInstitute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.ORCID 0000-0001-5417-9307
Sandra CiesekInstitute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.
Barbara S SchnierleDivision of Virology, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0001-9563-4564
Alexander W TarrSchool of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7 2UH, United Kingdom.ORCID 0000-0003-1009-0823
Eike SteinmannDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.
Christine GoffinetDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.ORCID 0000-0002-3959-004X
Stephanie PfaenderDepartment of Molecular and Medical Virology, Ruhr University Bochum, 44801 Bochum, Germany.
Jacomina Krijnse LockerElectron Microscopy of Pathogens, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Michael D MühlebachDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0002-7069-5018
Daniel TodtEuropean Virus Bioinformatics Center, 07743 Jena, Germany.ORCID 0000-0002-3564-1014
Richard J P BrownDivision of Veterinary Medicine, Paul-Ehrlich-Institut, 63225 Langen, Germany.ORCID 0000-0002-3292-6671

Funding

Bundesministerium für Bildung und Forschung (BMBF) 01KI2113Bundesministerium für Gesundheit (BMG) Charis 6aDeutsches Zentrum für Infektionsforschung (DZIF) TTU 01.805Deutsches Zentrum für Infektionsforschung (DZIF) TTU 01.922LOEWE-Zentrum für Translationale Medizin und Pharmakologie (TMP) DRUID-E7P
6 · The paper itself

Abstract

The accessory protease transmembrane protease serine 2 (TMPRSS2) enhances severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uptake into ACE2-expressing cells, although how increased entry impacts downstream viral and host processes remains unclear. To investigate this in more detail, we performed infection assays in engineered cells promoting ACE2-mediated entry with and without TMPRSS2 coexpression. Electron microscopy and inhibitor experiments indicated TMPRSS2-mediated cell entry was associated with increased virion internalization into endosomes, and partially dependent upon clathrin-mediated endocytosis. TMPRSS2 increased panvariant uptake efficiency and enhanced early rates of virus replication, transcription, and secretion, with variant-specific profiles observed. On the host side, transcriptional profiling confirmed the magnitude of infection-induced antiviral and proinflammatory responses were linked to uptake efficiency, with TMPRSS2-assisted entry boosting early antiviral responses. In addition, TMPRSS2-enhanced infections increased rates of cytopathology, apoptosis, and necrosis and modulated virus secretion kinetics in a variant-specific manner. On the virus side, convergent signatures of cell-uptake-dependent innate immune induction were recorded in viral genomes, manifesting as switches in dominant coupled Nsp3 residues whose frequencies were correlated to the magnitude of the cellular response to infection. Experimentally, we demonstrated that selected Nsp3 mutations conferred enhanced interferon antagonism. More broadly, we show that TMPRSS2 orthologues from evolutionarily diverse mammals facilitate panvariant enhancement of cell uptake. In summary, our study uncovers previously unreported associations, linking cell entry efficiency to innate immune activation kinetics, cell death rates, virus secretion dynamics, and convergent selection of viral mutations. These data expand our understanding of TMPRSS2's role in the SARS-CoV-2 life cycle and confirm its broader significance in zoonotic reservoirs and animal models.

Indexed as

COVID-19Immunity, InnateSARS-CoV-2Serine EndopeptidasesVirus InternalizationAngiotensin-Converting Enzyme 2AnimalsChlorocebus aethiopsCytodiagnosisEndocytosisHEK293 CellsHumansVirus ReplicationACE2 protein, humanAngiotensin-Converting Enzyme 2Serine EndopeptidasesTMPRSS2 protein, humancytolytic responseshost-species rangeinnate immunitySARS-CoV-2 entryviral evolution

Identifiers

PMID38814864
PMCPMC11161796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.